Biotechnology firm Atavistik Bio revealed on Thursday its new research partnership with Pfizer, Inc. aimed at advancing the discovery of innovative precision allosteric therapeutics to tackle substantial unaddressed medical conditions.
As part of this collaboration, Atavistik Bio will utilize its exclusive AMPS platform to identify novel allosteric binders for two unspecified targets chosen by Pfizer.
Upon concluding the research phase, Pfizer will have the opportunity to license the initiatives. The financial specifics of this collaboration remain confidential.
